Drug intelligence / Profile preview

PTP-01

Development stage: Phase 1
Lead developer: University of Virginia Foundation
Modality: Small Molecules, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
Administration: Intravenous

Overview

PTP-01 is a peptide conjugate radionuclide developed as a diagnostic radiopharmaceutical for use with SPECT (Single-photon emission computed tomography) imaging. It was initially developed by the University of Virginia Foundation to enhance the detection of pancreatic cancer, specifically pancreatic ductal adenocarcinoma, by targeting plectin—a biomarker highly specific to pancreatic cancer cells. The drug was designed to improve sensitivity in detecting small or early-stage pancreatic cancers that are often missed by conventional CT or MRI scans. Its mechanism involves acting as an enhancer for SPECT imaging, allowing better visualization of neoplastic tissue during diagnostic procedures[1].

Beyond the preview

Go deeper on PTP-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTP-01.

Explore the full profile